Report : Blood Plasma Derivatives Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, and Others), Application (Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, von Willebrand’s Diseases, and Others), and End User (Hospitals, Clinics, and Others)
Immunodeficiency Diseases Segment to Register Highest CAGR in Blood Plasma Derivatives Market During 2022–2028
According to our latest study on “Blood Plasma Derivatives Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Application, and End User,” the market is projected to reach US$ 51,119.24 million by 2028 from US$ 29,886.12 million in 2022; it is expected to record a CAGR of 9.4% from 2022 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.
The rising number of COVID-19 cases propelled the demand for blood plasma derivatives. Patients suffering from underlying immunodeficient disorders, including hypogammaglobulinemia and specific antibody deficiency (SDA), were at a greater risk of novel coronavirus infection and more likely to have higher morbidity and mortality. However, only essential procedures were allowed in hospitals during the lockdown, which delayed or canceled the immunoglobulin-based therapies. Additionally, various studies published in PubMed and NCBI by researchers show that intravenous immunoglobulin has demonstrated clinical efficacy in critically ill COVID-19 patients in reducing the rate of mortality. Post-COVID-19 pandemic, there has been a significant increase in the demand for plasma derivatives owing to the surge in immunoglobulin replacement therapies. Thus, the COVID-19 pandemic positively impacted the blood plasma derivatives market.
Based on type, the blood plasma derivatives market is segmented into immunoglobulins, albumin, factor VIII, factor IX, hyperimmune globulins, and others. In 2022, the immunoglobulin segment accounted for the largest market share. Also, the same segment is anticipated to register the highest CAGR during 2022–2028 due to high demand for immunoglobulins for immunoglobulin replacement therapy (IgRT). Based on application, the blood plasma derivatives market is segmented into immunodeficiency diseases, hemophilia, hypogammaglobulinemia, von Willebrand disease, and others. In 2022, the immunodeficiency diseases segment held the largest market share. Also, the same segment is expected to register the highest CAGR from 2022 to 2028. Based on end user, the global blood plasma derivatives market is segmented into hospitals, clinics, and others. The hospitals segment held the largest market share in 2022 and is anticipated to register the highest CAGR during the forecast period.
Plasma derivatives are obtained from explicit plasma proteins by the cycle of fractionation. Blood plasma derivatives contain a high amount of proteins, salts, minerals, hormones, vitamins, and protease inhibitors. Thus, they are commonly used in the treatment of bleeding disorders, hepatitis B, hepatitis C, hemophilia A, immunodeficiency, hypogammaglobulinemia, hemophilia B, and human immunodeficiency virus. The increasing prevalence of blood disorders and rising geriatric population drive the global blood plasma derivatives market growth. However, complicated reimbursement policies for plasma-based therapies in various nations hamper the market growth.
According to the National Organizations of Rare Disorders, hemophilia A is a common X-linked recessive disorder and the second most common inherited clotting factor deficiency after von Willebrand disease. According to the World Federation of Hemophilia (WFH) Annual Global Survey 2021, around 256,840 people across the world were affected by hemophilia in 2021. As per the WFH, in 2021, ~98,293 individuals globally had von Willebrand disease. Research published in NLM in 2020 stated that 80 million people in European Union suffer from blood disorders, ranging from cancer to bleeding disorders. According to National Organization for Rare Disorders, in 2022, immune thrombocytopenia (ITP), an autoimmune bleeding disorder, affects ~66 adults per 1 million in the US. Furthermore, the World Economic Forum reported in 2020 that more than 10% of the global population is affected by a rare disease. Since, plasma is a liquid portion of blood containing WBC and platelets. Blood plasma derivatives play a major role in treating many rare diseases. Thus, the increasing prevalence of blood disorders across the world promotes the blood plasma derivatives market growth.
Grifols SA, SK Plasma Co Ltd, Octapharma AG, Monobind Inc., Intas Pharmaceuticals Ltd, Fusion Health Care Pvt Ltd, Takeda Pharmaceutical Co Ltd, CSL Behring LLC, LFB SA, and Kedrion SpA are among the leading companies operating in the blood plasma derivatives market.
In terms of geography, the blood plasma derivatives market has been segmented as follows:
Based on geography, the blood plasma derivatives market is primarily segmented into North America, Europe, Asia Pacific (APAC), the Middle East & Africa (MEA), and South & Central America. The market in North America is further segmented into the US, Canada, and Mexico. The European market is subsegmented into France, Germany, the UK, Spain, Italy, and the Rest of Europe. The blood plasma derivatives market in APAC is subsegmented into Japan, China, India, Australia, South Korea, and the Rest of APAC. The market in the MEA is further segmented into Saudi Arabia, the UAE, South Africa, and the Rest of MEA. The market in South & Central America is further segmented into Brazil, Argentina, and the Rest of South & Central America.
Contact Person: Sameer Joshi
Email Id: firstname.lastname@example.org